Metformin and Rosiglitazone

Therapeutic indications

Metformin and Rosiglitazone is indicated for:

Diabetes mellitus type 2

Population group: only adults (18 years old or older)

Rosiglitazone/metformin combination is indicated in the treatment of type 2 diabetes mellitus patients, particularly overweight patients:

who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.
in triple oral therapy with sulphonylurea in patients with insufficient glycaemic control despite dual oral therapy with their maximally tolerated dose of metformin and a sulphonylurea.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

4 mg of rosiglitazone and 2000 mg of metformin in 2 divided doses daily and after 8 weeks 4-8 mg of rosiglitazone and 2000 mg of metformin in 2 divided doses daily

Contraindications

Metformin and Rosiglitazone is contraindicated in the following cases:

Lactation

Renal failure

Hepatic impairment

Hepatic insufficiency

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.